An experimental cancer drug discovered at Oxford university is the focus of a new UK biotech company to be listed in London this week led by two veterans of Bristol-Myers Squibb, the large US pharmaceuticals group.
SalvaRX has been set up with backing from Jim Mellon, the Isle of Man-based investor, as an incubator for early-stage cancer drug developers.
Its first asset is iOx Therapeutics which is working on treatments using so-called natural killer T-cells to attack tumours.
Failed Polish oil and gas investor 3Legs will relaunch on the junior market as a cancer drug company backed by multi-millionaire investor Jim Mellon. In the face of collapsing commodity prices the shale business has undergone a complete transformation after it announced an £8.8m reverse takeover of cancer immunotherapy development company SalvaRx. Shares will start trading on Tuesday at 35p with a £1.95m share placing also take place.
Tumors contain the seeds of their own destruction. We just need to work out how to activate them.
The rise of immunotherapy has been one of the most startling and promising developments in cancer research for some time. After decades of false starts and dead ends, scientists have finally found effective ways of marshaling the immune system to destroy cancers. Some use drugs called “checkpoint inhibitors” to lift the natural brakes that restrain immune cells, allowing them to go to town on tumors. Others are extracting, engineering, and re-injecting the immune cells themselves. The results have been staggering. Advanced cancers have gone into complete remission. People who were given months to live are still here years later.
Blueprint Medicines said today it is launching a $1 billion-plus collaboration with Roche to discover, develop, and commercialize up to five small-molecule therapeutics targeting kinases deemed important in cancer immunotherapy.
The five candidates could be either single products or products to be combined with Roche therapeutics.
Roche will hold options triggered upon achievement of Phase I proof-of-concept for an exclusive license to each drug candidate developed under the collaboration.
Blueprint Medicines will primarily oversee preclinical research and clinical development for each program before Roche exercises any option for it. Should Roche exercise an option for a program, Roche will be responsible for global development for that program through Phase III clinical trials.
The immune system can be a powerful weapon against cancer — but researchers are still grappling with how to control it.
The first tumour was a small melanoma on the left side of attorney Mark Gorman's neck. Doctors removed it, and assured him that the cancer was gone.
Just weeks after AstraZeneca ($AZN) reported a success for a combination study of durvalumab and tremelimumab, the pharma giant has been forced to concede that the CTLA-4 drug tremelimumab flunked a solo challenge for mesothelioma.